Latigo Biotherapeutics Secures $150 Million to Revolutionize Pain Management
March 18, 2025, 3:32 am
In a bold move that could reshape the landscape of pain management, Latigo Biotherapeutics has successfully closed a $150 million Series B financing round. This Thousand Oaks, California-based biotechnology company is on a mission to develop non-opioid pain treatments that target the source of pain, rather than merely masking it. The urgency for innovative solutions in pain management has never been more pressing, and Latigo is stepping up to the plate.
The financing round was led by Blue Owl Capital, a firm known for its strategic investments in promising biotech ventures. Other notable participants included Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital. Existing investors, such as Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments, also reaffirmed their commitment to Latigo’s vision.
With this influx of capital, Latigo plans to accelerate its development efforts. The company is focused on advancing its pipeline of highly selective Nav1.8 inhibitors, which are currently in clinical trials for treating both acute and chronic pain. This is not just a financial boost; it’s a lifeline for patients seeking alternatives to traditional opioid therapies.
Latigo’s lead candidate, LTG-001, is an oral, selective Nav1.8 inhibitor designed to tackle acute pain at its source. Recent Phase 1 trial results have shown that LTG-001 is well-tolerated and exhibits rapid absorption. This is a significant milestone, suggesting that the drug could provide effective pain relief without the addictive properties associated with opioids.
Another promising candidate, LTG-305, is also in Phase 1 clinical trials. This oral, selective Nav1.8 inhibitor aims to address chronic pain, a condition that affects millions of people worldwide. The trial is designed to evaluate safety, tolerability, and pharmacokinetics, ensuring that the drug can be administered safely to patients.
The need for non-opioid pain treatments is urgent. The opioid crisis has cast a long shadow over pain management, leaving many patients in search of safer alternatives. Latigo’s innovative approach offers a glimmer of hope. By targeting the underlying mechanisms of pain, these new treatments could change the way pain is managed, reducing reliance on opioids and their associated risks.
Kevin Raidy, a senior managing director at Blue Owl Capital, has joined Latigo’s board of directors as part of this financing round. His expertise in life sciences investing will be invaluable as Latigo navigates the complexities of drug development and market entry. The addition of Raidy signals a commitment to strategic growth and innovation.
Latigo’s CEO, Nima Farzan, emphasizes the transformative potential of their non-addictive pain treatments. The company is not just developing drugs; it is pioneering a new paradigm in pain management. The support from both new and existing investors underscores the confidence in Latigo’s mission and the urgent need for alternatives to opioids.
The landscape of pain management is ripe for disruption. Traditional methods often fall short, leaving patients in a cycle of pain and dependency. Latigo’s focus on non-opioid solutions could be the key to breaking this cycle. By harnessing the power of targeted therapies, the company aims to provide effective relief without the risks associated with opioids.
Investors are taking notice. The backing from prominent firms reflects a growing recognition of the need for innovation in this space. The financial support will enable Latigo to expand its operations and accelerate the development of its promising pipeline. This is not just about funding; it’s about fostering a new era of pain management.
As Latigo moves forward, the stakes are high. The company is poised to make a significant impact on the lives of patients suffering from pain. With a robust pipeline and strong investor support, Latigo is well-positioned to lead the charge in non-opioid pain therapeutics.
In conclusion, Latigo Biotherapeutics is at the forefront of a critical shift in pain management. The $150 million raised in Series B financing is more than just a financial milestone; it represents hope for millions seeking relief from pain without the burden of addiction. As the company advances its innovative therapies, the potential to transform the treatment landscape is within reach. The journey is just beginning, but the destination promises to be revolutionary.
The financing round was led by Blue Owl Capital, a firm known for its strategic investments in promising biotech ventures. Other notable participants included Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital. Existing investors, such as Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments, also reaffirmed their commitment to Latigo’s vision.
With this influx of capital, Latigo plans to accelerate its development efforts. The company is focused on advancing its pipeline of highly selective Nav1.8 inhibitors, which are currently in clinical trials for treating both acute and chronic pain. This is not just a financial boost; it’s a lifeline for patients seeking alternatives to traditional opioid therapies.
Latigo’s lead candidate, LTG-001, is an oral, selective Nav1.8 inhibitor designed to tackle acute pain at its source. Recent Phase 1 trial results have shown that LTG-001 is well-tolerated and exhibits rapid absorption. This is a significant milestone, suggesting that the drug could provide effective pain relief without the addictive properties associated with opioids.
Another promising candidate, LTG-305, is also in Phase 1 clinical trials. This oral, selective Nav1.8 inhibitor aims to address chronic pain, a condition that affects millions of people worldwide. The trial is designed to evaluate safety, tolerability, and pharmacokinetics, ensuring that the drug can be administered safely to patients.
The need for non-opioid pain treatments is urgent. The opioid crisis has cast a long shadow over pain management, leaving many patients in search of safer alternatives. Latigo’s innovative approach offers a glimmer of hope. By targeting the underlying mechanisms of pain, these new treatments could change the way pain is managed, reducing reliance on opioids and their associated risks.
Kevin Raidy, a senior managing director at Blue Owl Capital, has joined Latigo’s board of directors as part of this financing round. His expertise in life sciences investing will be invaluable as Latigo navigates the complexities of drug development and market entry. The addition of Raidy signals a commitment to strategic growth and innovation.
Latigo’s CEO, Nima Farzan, emphasizes the transformative potential of their non-addictive pain treatments. The company is not just developing drugs; it is pioneering a new paradigm in pain management. The support from both new and existing investors underscores the confidence in Latigo’s mission and the urgent need for alternatives to opioids.
The landscape of pain management is ripe for disruption. Traditional methods often fall short, leaving patients in a cycle of pain and dependency. Latigo’s focus on non-opioid solutions could be the key to breaking this cycle. By harnessing the power of targeted therapies, the company aims to provide effective relief without the risks associated with opioids.
Investors are taking notice. The backing from prominent firms reflects a growing recognition of the need for innovation in this space. The financial support will enable Latigo to expand its operations and accelerate the development of its promising pipeline. This is not just about funding; it’s about fostering a new era of pain management.
As Latigo moves forward, the stakes are high. The company is poised to make a significant impact on the lives of patients suffering from pain. With a robust pipeline and strong investor support, Latigo is well-positioned to lead the charge in non-opioid pain therapeutics.
In conclusion, Latigo Biotherapeutics is at the forefront of a critical shift in pain management. The $150 million raised in Series B financing is more than just a financial milestone; it represents hope for millions seeking relief from pain without the burden of addiction. As the company advances its innovative therapies, the potential to transform the treatment landscape is within reach. The journey is just beginning, but the destination promises to be revolutionary.